ArticleBlood cancer journal2024

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Rakesh Popat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.